<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008601</url>
  </required_header>
  <id_info>
    <org_study_id>AinoECG_Ambulatory</org_study_id>
    <nct_id>NCT05008601</nct_id>
  </id_info>
  <brief_title>Aino ECG Ambulatory Study</brief_title>
  <official_title>Detection of Cardiac Arrhythmias With Wrist-worn Combined Optical and ECG Based Heart Rate Monitor During Normal Daily Living</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PulseOn Oy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TAYS Sydänkeskus Oy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atostek Oy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PulseOn Oy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study includes collection of data from patients referred to a therapeutic evaluation in&#xD;
      Tays Sydänkeskus Oy (Heart Center Co, Tampere University Hospital) or another unit of&#xD;
      Sydänkeskus (hereafter the Heart Hospital) due to suspected cardiac arrhythmia. Data&#xD;
      collection takes place outside the hospital in normal daily conditions. The monitoring is&#xD;
      started during the outpatient visit at Heart hospital polyclinic or when leaving home from&#xD;
      cardiac ward and it continues for 2 days. Reference information about the occurrence of&#xD;
      arrhythmia episodes and the reference ECG data are obtained from simultaneously worn Holter&#xD;
      device.&#xD;
&#xD;
      During the two days the study device and the reference device are worn continuously. Wearing&#xD;
      the devices does not affect the daily routines of the participant except there is no&#xD;
      possibility to take a shower. The arrhythmia episodes are labelled in post-hoc signal&#xD;
      analysis and annotations visually confirmed by a cardiologist. The participants are&#xD;
      instructed to take ECG recordings with the wrist device every time the device gives a&#xD;
      notification and also whenever the participant feels arrhythmia symptoms. There will be at&#xD;
      least four intermittent ECG records taken on each day.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Verification that the atrial fibrillation detection sensitivity satisfies the design input requirements defined for the Aino ECG device</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Verification that the data accuracy (accuracy of optically measured inter-beat-intervals) satisfies the design input requirement defined for the Aino ECG device.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Verification that the quality of the ECG signal measured with Aino ECG satisfies the design input requirement defined for the Aino ECG device.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Showing that the quality of the measured PPG signal is similar enough compared with the one measured with the earlier prototype</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To obtain feedback regarding the usability of the Aino ECG wrist device</measure>
    <time_frame>6 months</time_frame>
    <description>The feedback is obtained with feedback form filled by the study participants. The form includes questions regarding: overall impression on the study device, easiness of noticing and interpret the notifications of the device, comfortability of using the device, easiness of adjusting the tightness of the wrist band, and operation of the intermittent ECG measurements.</description>
  </secondary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Arrhythmias, Cardiac</condition>
  <condition>Atrial Fibrillation and Flutter</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wrist-word optical heart rate and ECG measurement device</intervention_name>
    <description>Aino ECG: wrist-word optical heart rate and ECG measurement device</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The source population of the study includes patients referred to a therapeutic evaluation&#xD;
        or treatment in Tays Heart Hospital due to suspected cardiac arrhythmia. A portion (up to&#xD;
        one third) of the subjects may be having on-going atrial fibrillation at the beginning of&#xD;
        the measurement and may suffer from persistent or permanent atrial fibrillation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: ≥ 18 years&#xD;
&#xD;
          -  Suspected or earlier diagnosed episodic cardiac arrhythmia, for example atrial&#xD;
             fibrillation or atrial flutter&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
          -  Volunteering for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Implanted permanent pacemaker&#xD;
&#xD;
          -  Inability to give informed consent e.g. due to mental confusion&#xD;
&#xD;
          -  Denial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jussi Hernesniemi, Docent</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere Heart Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tampere Heart Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

